Patent intelligence · WO
WO 2022043557
MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA
MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA
Patent details — WO 2022043557
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Mar 3, 2022
- Expiration
- Feb 26, 2042
- CPC classes
- A61K 45/ 06 A I, A61K 51/ 04 A I, A61K/381774, A61K/381793
Quick answer
WO 2022043557 (MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA) is held by ADVANCED ACCELERATOR APPLICATIONS INT SA [CH]. Status: granted. Granted Mar 3, 2022. Expires Feb 26, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 45/ 06 A I, A61K 51/ 04 A I, A61K/381774, A61K/381793, A61K/382086, A61K/393955
More from ADVANCED ACCELERATOR APPLICATIONS INT SA [CH]
Related pharmaceutical patents in our USPTO index.
-
EP 4541380
STABILE KONZENTRIERTE RADIONUKLID-KOMPLEX-LÖSUNGEN
granted -
CA 3235923
PROCEDES DE SYNTHESE A GRANDE ECHELLE DE COMPLEXES DE RADIONUCLEIDES
granted -
CA 3240096
POLYTHERAPIE POUR LE TRAITEMENT DU CANCER DU POUMON
granted -
CA 3234495
POLYTHERAPIE DE COMPLEXE DE RADIONUCLEIDES
granted -
CA 3215723
PROCEDES DE DIAGNOSTIC DU CANCER DE LA PROSTATE
granted -
CA 3202908
ANTAGONISTE D'INTEGRINES ALPHA-V BETA-3 ET/OU ALPHA-V BETA-5 RADIOMARQUE DESTINE A ETRE UTILISE EN TANT QU'AGENT THERAGNOSTIQUE
granted -
US 2022072166
METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS
granted
Frequently asked questions
What is US patent 2022043557?
WO 2022043557 (MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA) is held by ADVANCED ACCELERATOR APPLICATIONS INT SA [CH]. Status: granted. Granted Mar 3, 2022. Expires Feb 26, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2022043557?
ADVANCED ACCELERATOR APPLICATIONS INT SA [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2022043557 expire?
Our index shows an expiration date of Feb 26, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.